Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stage
Author:
Toader Alice-MariaORCID, Campbell Marion K., Quint Jennifer K., Robling Michael, Sydes Matthew R, Thorn Joanna, Wright-Hughes Alexandra, Yu Ly-Mee, Abbott Tom. E. F., Bond Simon, Caskey Fergus J., Clout Madeleine, Collinson Michelle, Copsey Bethan, Davies Gwyneth, Driscoll Timothy, Gamble Carrol, Griffin Xavier L., Hamborg Thomas, Harris Jessica, Harrison David A., Harji Deena, Henderson Emily J., Logan Pip, Love Sharon B., Magee Laura A., O’Brien Alastair, Pufulete Maria, Ramnarayan Padmanabhan, Saratzis Athanasios, Smith Jo, Solis-Trapala Ivonne, Stubbs Clive, Farrin Amanda, Williamson Paula
Abstract
Abstract
Background
Healthcare system data (HSD) are increasingly used in clinical trials, augmenting or replacing traditional methods of collecting outcome data. This study, PRIMORANT, set out to identify, in the UK context, issues to be considered before the decision to use HSD for outcome data in a clinical trial is finalised, a methodological question prioritised by the clinical trials community.
Methods
The PRIMORANT study had three phases. First, an initial workshop was held to scope the issues faced by trialists when considering whether to use HSDs for trial outcomes. Second, a consultation exercise was undertaken with clinical trials unit (CTU) staff, trialists, methodologists, clinicians, funding panels and data providers. Third, a final discussion workshop was held, at which the results of the consultation were fed back, case studies presented, and issues considered in small breakout groups.
Results
Key topics included in the consultation process were the validity of outcome data, timeliness of data capture, internal pilots, data-sharing, practical issues, and decision-making. A majority of consultation respondents (n = 78, 95%) considered the development of guidance for trialists to be feasible. Guidance was developed following the discussion workshop, for the five broad areas of terminology, feasibility, internal pilots, onward data sharing, and data archiving.
Conclusions
We provide guidance to inform decisions about whether or not to use HSDs for outcomes, and if so, to assist trialists in working with registries and other HSD providers to improve the design and delivery of trials.
Funder
Health Data Research UK
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Sydes MR, Barbachano Y, Bowman L, Denwood T, Farmer A, Garfield-Birkbeck S, et al. Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open. 2021;11(6): e043906. 2. Lensen S, Macnair A, Love SB, Yorke-Edwards V, Noor NM, Martyn M, et al. Access to routinely collected health data for clinical trials–review of successful data requests to UK registries. Trials. 2020;21(1):1–11. 3. McKay AJ, Jones AP, Gamble CL, Farmer AJ, Williamson PR. Use of routinely collected data in a UK cohort of publicly funded randomised clinical trials. F1000Research. 2021;9:323. 4. Alice-Maria Toader, Carrol Gamble, Susanna Dodd, et al. The use of healthcare systems data for RCTs, 17 October 2023, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-3373403/v1]. 5. Williams AD, Davies G, Farrin AJ, Mafham M, Robling M, Sydes MR, et al. A DELPHI study priority setting the remaining challenges for the use of routinely collected data in trials: COMORANT-UK. Trials. 2023;24(1):1–8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. How should we measure the use of social care and informal care?;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-26
|
|